SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Logothetis Christopher J.)
 

Sökning: WFRF:(Logothetis Christopher J.) > (2015) > Abiraterone acetate...

  • Ryan, Charles JUniversity of California, San Francisco (författare)

Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302) : final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study

  • Artikel/kapitelEngelska2015

Förlag, utgivningsår, omfång ...

  • 2015
  • 9 s.

Nummerbeteckningar

  • LIBRIS-ID:oai:lup.lub.lu.se:5efd6db3-607a-4d21-9c64-cecf189d59d9
  • https://lup.lub.lu.se/record/5efd6db3-607a-4d21-9c64-cecf189d59d9URI
  • https://doi.org/10.1016/S1470-2045(14)71205-7DOI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:art swepub-publicationtype
  • Ämneskategori:ref swepub-contenttype

Anmärkningar

  • BACKGROUND: Abiraterone acetate plus prednisone significantly improved radiographic progression-free survival compared with placebo plus prednisone in men with chemotherapy-naive castration-resistant prostate cancer at the interim analyses of the COU-AA-302 trial. Here, we present the prespecified final analysis of the trial, assessing the effect of abiraterone acetate plus prednisone on overall survival, time to opiate use, and use of other subsequent therapies.METHODS: In this placebo-controlled, double-blind, randomised phase 3 study, 1088 asymptomatic or mildly symptomatic patients with chemotherapy-naive prostate cancer stratified by Eastern Cooperative Oncology performance status (0 vs 1) were randomly assigned with a permuted block allocation scheme via a web response system in a 1:1 ratio to receive either abiraterone acetate (1000 mg once daily) plus prednisone (5 mg twice daily; abiraterone acetate group) or placebo plus prednisone (placebo group). Coprimary endpoints were radiographic progression-free survival and overall survival analysed in the intention-to-treat population. The study is registered with ClinicalTrials.gov, number NCT00887198.FINDINGS: At a median follow-up of 49.2 months (IQR 47.0-51.8), 741 (96%) of the prespecified 773 death events for the final analysis had been observed: 354 (65%) of 546 patients in the abiraterone acetate group and 387 (71%) of 542 in the placebo group. 238 (44%) patients initially receiving prednisone alone subsequently received abiraterone acetate plus prednisone as crossover per protocol (93 patients) or as subsequent therapy (145 patients). Overall, 365 (67%) patients in the abiraterone acetate group and 435 (80%) in the placebo group received subsequent treatment with one or more approved agents. Median overall survival was significantly longer in the abiraterone acetate group than in the placebo group (34.7 months [95% CI 32.7-36.8] vs 30.3 months [28.7-33.3]; hazard ratio 0.81 [95% CI 0.70-0.93]; p=0.0033). The most common grade 3-4 adverse events of special interest were cardiac disorders (41 [8%] of 542 patients in the abiraterone acetate group vs 20 [4%] of 540 patients in the placebo group), increased alanine aminotransferase (32 [6%] vs four [<1%]), and hypertension (25 [5%] vs 17 [3%]).INTERPRETATION: In this randomised phase 3 trial with a median follow-up of more than 4 years, treatment with abiraterone acetate prolonged overall survival compared with prednisone alone by a margin that was both clinically and statistically significant. These results further support the favourable safety profile of abiraterone acetate in patients with chemotherapy-naive metastatic castration-resistant prostate cancer.FUNDING: Janssen Research & Development.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Smith, Matthew RMassachusetts General Hospital (författare)
  • Fizazi, KarimUniversity of Paris-Saclay (författare)
  • Saad, FredUniversity Of Quebec In Montreal (författare)
  • Mulders, Peter F ARadboud University Medical Center (författare)
  • Sternberg, Cora NAzienda Ospedaliera San Camillo Forlanini (författare)
  • Miller, KurtCharité - University Medicine Berlin (författare)
  • Logothetis, Christopher JUniversity of Texas (författare)
  • Shore, Neal DCarolina Urologic Research Center (författare)
  • Small, Eric JUniversity of California, San Francisco (författare)
  • Carles, JoanVall d'Hebron University Hospital (författare)
  • Flaig, Thomas WUniversity of Colorado (författare)
  • Taplin, Mary-EllenDana-Farber Cancer Institute (författare)
  • Higano, Celestia SUniversity of Washington, Seattle (författare)
  • de Souza, PaulWestern Sydney University,Ingham Institute for Applied Medical Research (författare)
  • de Bono, Johann SRoyal Marsden Hospital, Sutton (författare)
  • Griffin, Thomas WJanssen Pharmaceuticals, US (författare)
  • De Porre, PeterJanssen Research & Development, Belgium (författare)
  • Yu, Margaret KJanssen Pharmaceuticals, US (författare)
  • Park, Youn CJanssen Pharmaceuticals, US (författare)
  • Li, JinhuiJanssen Pharmaceuticals, US (författare)
  • Kheoh, ThianJanssen Pharmaceuticals, US (författare)
  • Naini, VahidJanssen Pharmaceuticals, US (författare)
  • Molina, ArturoJanssen Pharmaceuticals, US (författare)
  • Rathkopf, Dana EMemorial Sloan-Kettering Cancer Center (författare)
  • Bjartell, AndersLund University,Lunds universitet,Urologisk cancerforskning, Malmö,Forskargrupper vid Lunds universitet,Urological cancer, Malmö,Lund University Research Groups(Swepub:lu)kir-abj (creator_code:cre_t)
  • University of California, San FranciscoMassachusetts General Hospital (creator_code:org_t)
  • COU-AA-302 Investigators

Sammanhörande titlar

  • Ingår i:The Lancet Oncology16:2, s. 60-1521474-5488

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy